Navigation Links
Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health

LONDON, May 31, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Bellus Health (TSX: BLU), a Canadian pharmaceutical company developing drugs for amyloid-related diseases.

Edison has recently published a comprehensive report examining the investment merits of Bellus Health, focusing on the company's lead programme, Kiacta, currently in a pivotal Phase III trial for amyloid A (AA) amyloidosis, an orphan drug indication affecting up to 50,000 patients worldwide. In the report, Pivotal play in rare kidney disease, Edison's Canadian-based healthcare analyst, Pooya Hemami , argues that Bellus' investment case is underpinned by Kiacta's 60% probability of success in the pivotal study (based on positive trends in a previous Phase II/III study), the potential for premium pricing and a seven- to-10-year orphan drug market exclusivity period. With the Kiacta trial results not expected until 2017, a long-term view is required, but importantly, Bellus is fully funded until the data read out. Based on a risk-adjusted NPV analysis, Edison values Bellus at C$31m, or C$0.74 per share (fully diluted).


For the full report see:

The launch of coverage on Bellus Health is part of a programme of research initiations on healthcare companies worldwide. Edison provides research coverage on more than 130 healthcare companies in Europe, North America and Australia. Edison has pioneered a scientific, detail-oriented approach to analysing companies in the healthcare sector that is delivered in a concise and non-promotional manner. It aims to inform investors, while providing a realistic assessment of the competitive strengths and threats to key drug development programmes. All facts are carefully sourced and the analysis is underpinned by comprehensive and rigorous financial models. Edison's reports provide an overall company valuation without any specific stock recommendation.

All reports published by Edison are available to download free of charge from its website

About Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

About Bellus Health

Bellus Health is a Canadian pharmaceutical company developing drugs for amyloid-related diseases. Its lead candidate, Kiacta, is in a pivotal Phase III trial for amyloid A (AA) amyloidosis. BLU8499 is expected to start a Phase IIa study in Alzheimer's disease in 2014. Vivimind, a nutraceutical product for memory support, is marketed through distribution agreements with multiple partners in several countries, including Italy, Canada and Greece. For more information, visit

For more information please contact:
Pooya Hemami , Edison Investment Research, +1-514-475-2384

SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
2. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
3. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
4. Edison Pharmaceuticals Closes $20M Series F Financing
5. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
6. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
7. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
8. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
9. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
10. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
11. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015  At this year,s ... to experience the most complete mobile C-arm portfolio with ... is Ziehm Vision RFD 3D, the world,s only 3D ... edge length per scan volume. In addition, Ziehm Imaging ... motorized mobile C-arm in four axes which is ideally ...
(Date:11/29/2015)... CORALVILLE, Iowa , Nov. 29, 2015 /PRNewswire/ ... in ultrasound guidance technology at the Radiological Society ... conference in Chicago November ... guidance system is designed to offer customers unrivaled ... outcomes. --> ...
(Date:11/27/2015)... 2015 Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... Une nouvelle approche consistant à combiner l,immunothérapie au ...    Clinical Cancer Research . ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... Effective immediately, every single IguanaMed scrub style ... Black Friday Target is offering a “Buy One Scrub Set, Get the 2nd Scrub ... to purchase IguanaMed at a discounted price. , IguanaMed’s mission is to ...
(Date:11/28/2015)... ... ... Safe storage for contraceptive devices may not always be easy to find. ... the other from Bradley Beach, New Jersey, there is an easy solution to the ... replace NuvaRings more often than necessary. As such, it affords peace of mind and ...
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... by the University of Toronto and the University of British Columbia suggested that laws ... head injuries. The article explains that part of the reason for the controversial conclusion ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
Breaking Medicine News(10 mins):